Development of a new family of cyclophilin inhibitors with broad antiviral spectrum and study of their mechanisms of action in Hepatitis C Virus and Coronavirus infections.
Identifieur interne : 000028 ( France/Analysis ); précédent : 000027; suivant : 000029Development of a new family of cyclophilin inhibitors with broad antiviral spectrum and study of their mechanisms of action in Hepatitis C Virus and Coronavirus infections.
Auteurs : Quentin Nevers [France]Source :
Descripteurs français
English descriptors
Abstract
Over the past decades, an increasing number of viruses has emerged or re-emerged in humans. Unfortunately, currently approved antiviral drugs target a small set of viruses. Thus, there is an urgent need for the development of broad-spectrum antiviral drugs.Cyclophilins are cellular proteins involved in a large number of biological processes, and in different viral lifecycles from unrelated families. They appear as a potential target for the development of broad-spectrum antiviral approaches. However, currently available cyclophilin inhibitors have drawbacks which limit their clinical use.By means of "fragment-based drug design", we generated a new class of small-molecule cyclophilin inhibitors (SMCypI), unrelated with those already available. Cristallographic studies revealed that the SMCypIs bind to two close pockets of the active site and inhibit cyclophilin PPIase activity. These compounds do not bear immunosuppressive properties and inhibit the replication of HIV, HCV and coronaviruses in vitro.We characterized the anti-HCV activity of C31, the most potent inhibitor of cyclophilin PPIase activity. C31 had pan-genotypic HCV inhibitor properties, with a high barrier to resistance and additive effects with currently approved anti-HCV agents. C31 blocked HCV replication by disrupting the interaction between the nonstructural viral protein NS5A and cyclophilin A in a PPIase-dependent manner. Finally, C31 was active on zika, yellow fever, dengue and West-Nile virus infections.The antiviral activity of the SMCypIs has then been characterized on HCoV-229E infection. Interestingly, PPIase inhibition was necessary, but not sufficient for antiviral effect. A structure-activity relationship study identified a key moiety in the SMCypIs at the interface between the two cyclophilin pockets. F836 has been identified as the most potent compound which inhibited both the cytopathic effect and the intracellular RNA of HCoV-229E without associated cytotoxicity and as potently as alisporivir. This compound targeted HCoV-229E entry at a post-attachment step and was also active on HCoV-OC43 and MERS-CoV strains. We then demonstrated that cyclophilin A was associated with viral particles. By means of CRISPR-Cas9, cell lines depleted for cyclophilin A were generated. Cyclophilin A was identified as a proviral factor for HCoV-229E and was partially involved in F836 antiviral effect. Cyclophilin A expression level was drastically decreased by infection.SMCypIs represent a unique tool to decipher the cellular and molecular mechanisms by which cyclophilins interfere with viral lifecycles, as well as drugable compounds that could find an indication as broad-spectrum antiviral drugs.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Hal, to step Corpus: 000006
- to stream Hal, to step Curation: 000006
- to stream Hal, to step Checkpoint: 000004
- to stream Main, to step Merge: 000757
- to stream Main, to step Curation: 000754
- to stream Main, to step Exploration: 000754
- to stream France, to step Extraction: 000028
Links to Exploration step
Hal:tel-01945254Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a new family of cyclophilin inhibitors with broad antiviral spectrum and study of their mechanisms of action in Hepatitis C Virus and Coronavirus infections.</title>
<title xml:lang="fr">Développement d'une nouvelle famille d'inhibiteurs de cyclophilines à large spectre antiviral et étude de leurs mécanismes d'action dans les infections par le Virus de l'Hépatite C et les Coronavirus.</title>
<author><name sortKey="Nevers, Quentin" sort="Nevers, Quentin" uniqKey="Nevers Q" first="Quentin" last="Nevers">Quentin Nevers</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-266797" status="VALID"> <idno type="IdRef">151294895</idno>
<idno type="RNSR">200919261B</idno>
<orgName>Institut Mondor de Recherche Biomédicale</orgName>
<orgName type="acronym">IMRB</orgName>
<desc> <address> <addrLine>8 rue du Général Sarrail 94010 Créteil</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.imrb.inserm.fr/</ref>
</desc>
<listRelation> <relation name="U955" active="#struct-303623" type="direct"></relation>
<relation active="#struct-305148" type="direct"></relation>
<relation name="UMR955" active="#struct-420786" type="direct"></relation>
</listRelation>
<tutelles><tutelle name="U955" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-305148" type="direct"><org type="institution" xml:id="struct-305148" status="INCOMING"> <orgName>IFR10</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
<tutelle name="UMR955" active="#struct-420786" type="direct"><org type="institution" xml:id="struct-420786" status="VALID"> <idno type="IdRef">028021037</idno>
<idno type="ISNI">0000000121497878</idno>
<orgName>Université Paris-Est Créteil Val-de-Marne - Paris 12</orgName>
<orgName type="acronym">UPEC UP12</orgName>
<date type="start">1970-01-01</date>
<desc> <address> <addrLine>61 avenue du Général de Gaulle - 94010 Créteil cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-pec.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:tel-01945254</idno>
<idno type="halId">tel-01945254</idno>
<idno type="halUri">https://tel.archives-ouvertes.fr/tel-01945254</idno>
<idno type="url">https://tel.archives-ouvertes.fr/tel-01945254</idno>
<date when="2018-01-31">2018-01-31</date>
<idno type="wicri:Area/Hal/Corpus">000006</idno>
<idno type="wicri:Area/Hal/Curation">000006</idno>
<idno type="wicri:Area/Hal/Checkpoint">000004</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000004</idno>
<idno type="wicri:Area/Main/Merge">000757</idno>
<idno type="wicri:Area/Main/Curation">000754</idno>
<idno type="wicri:Area/Main/Exploration">000754</idno>
<idno type="wicri:Area/France/Extraction">000028</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a new family of cyclophilin inhibitors with broad antiviral spectrum and study of their mechanisms of action in Hepatitis C Virus and Coronavirus infections.</title>
<title xml:lang="fr">Développement d'une nouvelle famille d'inhibiteurs de cyclophilines à large spectre antiviral et étude de leurs mécanismes d'action dans les infections par le Virus de l'Hépatite C et les Coronavirus.</title>
<author><name sortKey="Nevers, Quentin" sort="Nevers, Quentin" uniqKey="Nevers Q" first="Quentin" last="Nevers">Quentin Nevers</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-266797" status="VALID"> <idno type="IdRef">151294895</idno>
<idno type="RNSR">200919261B</idno>
<orgName>Institut Mondor de Recherche Biomédicale</orgName>
<orgName type="acronym">IMRB</orgName>
<desc> <address> <addrLine>8 rue du Général Sarrail 94010 Créteil</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.imrb.inserm.fr/</ref>
</desc>
<listRelation> <relation name="U955" active="#struct-303623" type="direct"></relation>
<relation active="#struct-305148" type="direct"></relation>
<relation name="UMR955" active="#struct-420786" type="direct"></relation>
</listRelation>
<tutelles><tutelle name="U955" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-305148" type="direct"><org type="institution" xml:id="struct-305148" status="INCOMING"> <orgName>IFR10</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
<tutelle name="UMR955" active="#struct-420786" type="direct"><org type="institution" xml:id="struct-420786" status="VALID"> <idno type="IdRef">028021037</idno>
<idno type="ISNI">0000000121497878</idno>
<orgName>Université Paris-Est Créteil Val-de-Marne - Paris 12</orgName>
<orgName type="acronym">UPEC UP12</orgName>
<date type="start">1970-01-01</date>
<desc> <address> <addrLine>61 avenue du Général de Gaulle - 94010 Créteil cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-pec.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</analytic>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>Antiviral</term>
<term>Broad Spectrum</term>
<term>Coronavirus</term>
<term>Cyclophilins</term>
<term>Hepatitis C Virus</term>
<term>Inhibitors</term>
</keywords>
<keywords scheme="mix" xml:lang="fr"><term>Antiviral</term>
<term>Coronavirus</term>
<term>Cyclophilines</term>
<term>Inhibiteurs</term>
<term>Large spectre</term>
<term>Virus de l'Hépatite C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"> <p>Over the past decades, an increasing number of viruses has emerged or re-emerged in humans. Unfortunately, currently approved antiviral drugs target a small set of viruses. Thus, there is an urgent need for the development of broad-spectrum antiviral drugs.Cyclophilins are cellular proteins involved in a large number of biological processes, and in different viral lifecycles from unrelated families. They appear as a potential target for the development of broad-spectrum antiviral approaches. However, currently available cyclophilin inhibitors have drawbacks which limit their clinical use.By means of "fragment-based drug design", we generated a new class of small-molecule cyclophilin inhibitors (SMCypI), unrelated with those already available. Cristallographic studies revealed that the SMCypIs bind to two close pockets of the active site and inhibit cyclophilin PPIase activity. These compounds do not bear immunosuppressive properties and inhibit the replication of HIV, HCV and coronaviruses in vitro.We characterized the anti-HCV activity of C31, the most potent inhibitor of cyclophilin PPIase activity. C31 had pan-genotypic HCV inhibitor properties, with a high barrier to resistance and additive effects with currently approved anti-HCV agents. C31 blocked HCV replication by disrupting the interaction between the nonstructural viral protein NS5A and cyclophilin A in a PPIase-dependent manner. Finally, C31 was active on zika, yellow fever, dengue and West-Nile virus infections.The antiviral activity of the SMCypIs has then been characterized on HCoV-229E infection. Interestingly, PPIase inhibition was necessary, but not sufficient for antiviral effect. A structure-activity relationship study identified a key moiety in the SMCypIs at the interface between the two cyclophilin pockets. F836 has been identified as the most potent compound which inhibited both the cytopathic effect and the intracellular RNA of HCoV-229E without associated cytotoxicity and as potently as alisporivir. This compound targeted HCoV-229E entry at a post-attachment step and was also active on HCoV-OC43 and MERS-CoV strains. We then demonstrated that cyclophilin A was associated with viral particles. By means of CRISPR-Cas9, cell lines depleted for cyclophilin A were generated. Cyclophilin A was identified as a proviral factor for HCoV-229E and was partially involved in F836 antiviral effect. Cyclophilin A expression level was drastically decreased by infection.SMCypIs represent a unique tool to decipher the cellular and molecular mechanisms by which cyclophilins interfere with viral lifecycles, as well as drugable compounds that could find an indication as broad-spectrum antiviral drugs.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
</list>
<tree><country name="France"><noRegion><name sortKey="Nevers, Quentin" sort="Nevers, Quentin" uniqKey="Nevers Q" first="Quentin" last="Nevers">Quentin Nevers</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000028 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000028 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= France |étape= Analysis |type= RBID |clé= Hal:tel-01945254 |texte= Development of a new family of cyclophilin inhibitors with broad antiviral spectrum and study of their mechanisms of action in Hepatitis C Virus and Coronavirus infections. }}
This area was generated with Dilib version V0.6.33. |